ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2024
Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease.
Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Plasma Neurofilament Light Chain as a Complementary Biomarker for Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2026Pooled it
- Digital memory assessments and plasma pTau217 enable efficient preclinical Alzheimer's trials.The journal of prevention of Alzheimer's disease · 2026Trial
- Cerebrospinal Fluid Biomarker Ratio Concordance with Amyloid Positron-Emission Tomography: A Diagnostic Test Accuracy Meta-analysis.Neurology and therapy · 2026Article
- Alzheimer's Disease Biomarkers Measured by Capillary Blood Collection Versus Venous Plasma and Cerebrospinal Fluid.Annals of clinical and translational neurology · 2026Article
- Article
- Review
- Evaluating digital cognitive tests for clinical use in Alzheimer's disease: A novel framework and scoping review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Lecanemab use in Chinese patients with Alzheimer's disease: a 12-month multicenter real-world study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Observational
- Clinical implementation of digital cognitive assessments - recommendations from Global CEO Initiative on Alzheimer's Disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Multicenter validation of plasma p-tau217/ amyloid beta 1-42 ratio in symptomatic Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Comparison of two analytical platforms for quantification of neuroglial biomarkers in blood samples: a single molecule array and an electrochemiluminescence assay.Scientific reports · 2026Article
- Head-to-head comparison of neurodegeneration biomarkers across two analytical platforms in Alzheimer's disease.Aging clinical and experimental research · 2026Article
- The cost of dementia in the United States in 2026.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Plasma biomarkers for Alzheimer disease: the road from laboratory results to clinical practice.Nature reviews. Neurology · 2026Article
- What Does a Positive Alzheimer Disease Blood-Based Biomarker Result Mean in People With Mild Cognitive Impairment?Neurology · 2026Review
- Common Medical Comorbidities, Demographic Factors and Levels of Plasma Biomarkers of Alzheimer's Disease and Neurodegeneration in Black/African American Older Adults.Biomolecules · 2026Article
- Streamlining Alzheimer's disease diagnosis: real-world validation of two-cut-off diagnostic models based on plasma p-tau/Aβ42 ratios.Journal of neurology · 2026Article
- Factors influencing implementation of an Alzheimer's disease blood test among UK old age psychiatrists: mixed-methods study using the theoretical domains framework.Age and ageing · 2026Article
- Dementia diagnostic deserts: workforce and geographic inequities in the diagnostic pathway for cognitive impairment.Health affairs scholar · 2026Article
- Diagnostic performance of plasma p-tau217 levels measured with different assays for Alzheimer's disease.Translational psychiatry · 2026Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Funding
Abstract
Blood-based biomarkers (BBM) for Alzheimer's disease (AD) are being increasingly used in clinical practice to support an AD diagnosis. In contrast to traditional diagnostic modalities, such as amyloid positron emission tomography and cerebrospinal fluid biomarkers, BBMs offer a more accessible and lower cost alternative for AD biomarker testing. Their unique scalability addresses the anticipated surge in demand for biomarker testing with the emergence of disease-modifying treatments (DMTs) that require confirmation of amyloid pathology. To facilitate the uptake of BBMs in clinical practice, The Global CEO Initiative on Alzheimer's Disease convened a BBM Workgroup to provide recommendations for two clinical implementational pathways for BBMs: one for current use for triaging and another for future use to confirm amyloid pathology. These pathways provide a standardized diagnostic approach with guidance on interpreting BBM test results. Integrating BBMs into clinical practice will simplify the diagnostic process and facilitate timely access to DMTs for eligible patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.